Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lonafarnib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA known ✓ | P49354 | 20/20 | 1.00 |
| ▸ | FNTB known ✓ | P49356 | 20/20 | 1.00 |
| ▸ | HRAS | P01112 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lonafarnib SCHEMBL94653 | 1.00 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| Lonafarnib SCHEMBL29517258 | 1.00 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| Lonafarnib SCHEMBL19032 | 1.00 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL13578722 | 0.93 | FNTA (0.88) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL6956843 | 0.93 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL17547678 | 0.92 | FNTA (0.86) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL31510741 | 0.92 | FNTA (1.00) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL13524750 | 0.92 | FNTA (0.85) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL12022170 | 0.92 | FNTA (0.85) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL14148187 | 0.92 | FNTA (0.85) | FNTAFNTBHRASKRASABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3385395-B9 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | KURA ONCOLOGY INC (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3385395-B1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | KURA ONCOLOGY INC (US) | 2020-01-29 | — | — | EP | disclosed |